531 related articles for article (PubMed ID: 20226197)
1. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
3. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
[TBL] [Abstract][Full Text] [Related]
6. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
7. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
Huang D; Qi Y; Song J; Zhang JZH
J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
[TBL] [Abstract][Full Text] [Related]
8. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
9. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
Li X; Liu C; Chen S; Hu H; Su J; Zou Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
[TBL] [Abstract][Full Text] [Related]
10. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
[TBL] [Abstract][Full Text] [Related]
11. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
12. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
13. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
14. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
15. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
16. An ultrahigh affinity d-peptide antagonist Of MDM2.
Zhan C; Zhao L; Wei X; Wu X; Chen X; Yuan W; Lu WY; Pazgier M; Lu W
J Med Chem; 2012 Jul; 55(13):6237-41. PubMed ID: 22694121
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
Lu SY; Jiang YJ; Zou JW; Wu TX
J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of how stress-induced MDMX phosphorylation activates p53.
Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
[TBL] [Abstract][Full Text] [Related]
20. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
Chen J; Zhang D; Zhang Y; Li G
Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
